DARZALEX intravenous drip infusion 100 mg, 400 mg Special Drug Use Results Survey (Recurrent or refractory multiple myeloma)

Trial Profile

DARZALEX intravenous drip infusion 100 mg, 400 mg Special Drug Use Results Survey (Recurrent or refractory multiple myeloma)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Feb 2018

At a glance

  • Drugs Daratumumab (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Janssen Pharmaceutical KK
  • Most Recent Events

    • 12 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top